Patents by Inventor Glenn T. Huang

Glenn T. Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190167858
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.
    Type: Application
    Filed: February 11, 2019
    Publication date: June 6, 2019
    Inventors: Glenn T. Huang, Brittany Jackson, James A. Burke, Ton Lin, Patrick M. Hughes, Larry A. Wheeler, Rosy Sheng Donn
  • Publication number: 20190105330
    Abstract: The present embodiments provide for a treatment regimen and use of a short-term sustained release liquid formulation of dexamethasone in citrate, wherein a single administration of a minute dosage form into the anterior chamber of the eye provides for anti-inflammatory therapy following cataract surgery
    Type: Application
    Filed: December 10, 2018
    Publication date: April 11, 2019
    Inventors: Vernon G. WONG, William S. WHITE, Mae W. HU, Glenn T. HUANG, Faina KARASINA
  • Patent number: 10201641
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: February 12, 2019
    Assignee: Allergan, Inc.
    Inventors: Glenn T. Huang, Brittany Jackson, James A. Burke, Ton Lin, Patrick M. Hughes, Larry A. Wheeler, Rosy Sheng Donn
  • Patent number: 10159683
    Abstract: The present embodiments provide for a treatment regimen and use of a short-term sustained release liquid formulation of dexamethasone in citrate, wherein a single administration of a minute dosage form into the anterior chamber of the eye provides for anti-inflammatory therapy following cataract surgery.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: December 25, 2018
    Assignee: ICON BIOSCIENCE, INC.
    Inventors: Vernon G. Wong, William S. White, Mae W. Hu, Glenn T. Huang, Faina Karasina
  • Publication number: 20180303851
    Abstract: The present embodiments provide for a treatment regimen and use of a short-term sustained release liquid formulation of dexamethasone in citrate, wherein a single administration of a minute dosage form into the anterior chamber of the eye provides for anti-inflammatory therapy following cataract surgery
    Type: Application
    Filed: June 26, 2018
    Publication date: October 25, 2018
    Inventors: Vernon G. WONG, William S. WHITE, Mae W. HU, Glenn T. HUANG, Faina KARASINA
  • Publication number: 20180296765
    Abstract: The present embodiments provide for simple devices that guide the loading and dispensing of accurate small doses of fluid from standard injection syringes.
    Type: Application
    Filed: June 19, 2018
    Publication date: October 18, 2018
    Inventors: Vernon G. WONG, Tan PHAM, William S. WHITE, Glenn T. HUANG, Mae W. HU
  • Patent number: 10028965
    Abstract: The present embodiments provide for a treatment regimen and use of a short-term sustained release liquid formulation of dexamethasone in citrate, wherein a single administration of a minute dosage form into the anterior chamber of the eye provides for anti-inflammatory therapy following cataract surgery.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: July 24, 2018
    Assignee: ICON BIOSCIENCE, INC.
    Inventors: Vernon G. Wong, William S. White, Mae W. Hu, Glenn T. Huang, Faina Karasina
  • Patent number: 10022502
    Abstract: Devices that guide the accurate loading and dispensing of predetermined doses of fluid from injection syringes are disclosed.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: July 17, 2018
    Assignee: ICON BIOSCIENCE, INC.
    Inventors: Vernon G. Wong, Tan Pham, William S. White, Glenn T. Huang, Mae W. Hu
  • Patent number: 9814773
    Abstract: The present invention provides for injectable pharmaceutical sustained release formulations for delivery of active agents, particularly therapeutic proteins, to the eye. The formulations are biocompatible, biodegradable sustained release formulations comprising low-solubility liquid excipients and relatively small amounts (less than about 10%) of biocompatible, biodegradable polymer such as PLA or PLGA polymers. A unit dose of 5 ?L to 100 ?L of the formulation provides for sustained release of the agent for at least 14 days.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: November 14, 2017
    Assignees: Ramscor, Inc., Icon Bioscience, Inc.
    Inventors: Vernon G. Wong, Louis L. Wood, Carol Wood, Glenn T. Huang
  • Patent number: 9636347
    Abstract: The present embodiments provide for methods of treating elevated intraocular pressure or glaucoma using a sustained release medicament consisting of prostaglandin in benzyl benzoate that is injected intraocularly no more frequently than once every two months.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: May 2, 2017
    Assignee: Icon Bioscience, Inc.
    Inventors: Vernon G. Wong, Mae W. Hu, Glenn T. Huang
  • Publication number: 20160243032
    Abstract: Biocompatible intraocular implants include a steroid and an auxiliary agent, where the auxiliary agent is present in an amount sufficient to lessen the severity of at least one side effect compared to the use of an otherwise identical implant lacking said auxiliary agent. The steroid and the auxiliary agent may be present on the same intraocular implant or on different implants. The steroid and auxiliary agent may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants containing the steroid and an auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the side effects otherwise accompanying steroid use.
    Type: Application
    Filed: May 2, 2016
    Publication date: August 25, 2016
    Inventors: Glenn T. Huang, Thierry Nivaggioli, Lon T. Spada, Hiroshi Sugimoto, Wendy M. Blanda, James N. Chang, Orest Olejnik
  • Publication number: 20160151386
    Abstract: The present embodiments provide for methods of treating elevated intraocular pressure or glaucoma using a sustained release medicament consisting of prostaglandin in benzyl benzoate that is injected intraocularly no more frequently than once every two months.
    Type: Application
    Filed: February 8, 2016
    Publication date: June 2, 2016
    Inventors: Vernon G. Wong, Mae W. Hu, Glenn T. Huang
  • Publication number: 20160120879
    Abstract: The present embodiments provide for a treatment regimen and use of a short-term sustained release liquid formulation of dexamethasone in citrate, wherein a single administration of a minute dosage form into the anterior chamber of the eye provides for anti-inflammatory therapy following cataract surgery
    Type: Application
    Filed: May 23, 2014
    Publication date: May 5, 2016
    Inventors: Vernon G. Wong, William S. White, Mae W. Hu, Glenn T. Huang, Faina Karasina
  • Patent number: 9327059
    Abstract: Biocompatible intraocular implants include a steroid and an auxiliary agent, where the auxiliary agent is present in an amount sufficient to lessen the severity of at least one side effect compared to the use of an otherwise identical implant lacking said auxiliary agent. The steroid and the auxiliary agent may be present on the same intraocular implant or on different implants. The steroid and auxiliary agent may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants containing the steroid and an auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the side effects otherwise accompanying steroid use.
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: May 3, 2016
    Assignee: Allergan, Inc.
    Inventors: Glenn T. Huang, Thierry Nivaggioli, Lon T. Spada, Hiroshi Sugimoto, Wendy M. Blanda, James N. Chang, Orest Olejnik
  • Patent number: 9283231
    Abstract: The present embodiments provide for methods of treating elevated intraocular pressure or glaucoma using a sustained release medicament consisting of prostaglandin in benzyl benzoate that is injected intraocularly no more frequently than once every two months.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: March 15, 2016
    Assignee: Icon Bioscience, Inc.
    Inventors: Vernon G. Wong, Mae W. Hu, Glenn T. Huang
  • Publication number: 20160038654
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.
    Type: Application
    Filed: October 19, 2015
    Publication date: February 11, 2016
    Inventors: Glenn T. Huang, Brittany Jackson, James A. Burke, Ton Lin, Patrick M. Hughes, Larry A. Wheeler, Rosy Sheng Donn
  • Publication number: 20160008354
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like.
    Type: Application
    Filed: September 22, 2015
    Publication date: January 14, 2016
    Inventors: Glenn T. Huang, James A. Burke, Patrick M. Hughes, Kai-Ming Zhang, Ton Lin, Larry A. Wheeler, Rosy Sheng Donn
  • Patent number: 9161938
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.
    Type: Grant
    Filed: January 31, 2008
    Date of Patent: October 20, 2015
    Assignee: Allergan, Inc.
    Inventors: Glenn T. Huang, Brittany Jackson, James A. Burke, Ton Lin, Patrick M. Hughes, Larry A. Wheeler, Rosy Sheng Donn
  • Patent number: 9144543
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like.
    Type: Grant
    Filed: April 22, 2013
    Date of Patent: September 29, 2015
    Assignee: Allergan, Inc.
    Inventors: Glenn T. Huang, James A. Burke, Patrick M. Hughes, Kai-Ming Zhang, Ton Lin, Larry A. Wheeler, Rosy Sheng
  • Patent number: 8962009
    Abstract: Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: February 24, 2015
    Assignee: Allergan, Inc.
    Inventors: Glenn T. Huang, Thierry Nivaggioli